LactoSpore® (Heat-Stable Bacillus coagulans MTCC 5856 — Sabinsa)

Bacillus coagulans
Evidence Level
Limited
5 Clinical Trials
6 Documented Benefits
2/5 Evidence Score

LactoSpore from Sabinsa is one specific strain of the spore-forming, lactic acid-producing bacterium Bacillus coagulans, deposited as MTCC 5856 (newer papers call the species Weizmannia coagulans). Results for one probiotic strain do not carry over to another. It is sold as dormant spores, and in the maker's laboratory tests the spores withstood heat and simulated stomach acid. In 70 adults with functional gas and bloating, 2 billion spores a day for 4 weeks lowered gas and bloating scores more than placebo. Smaller pilots in diarrhea-type IBS, where everyone also took prescription drugs, and in adults with major depression and IBS also reported gains over placebo. In healthy adults, gut bacteria and abdominal comfort barely changed. Every trial was run by the maker and none has been independently repeated. It is not a treatment for any disease.

Studied Dose 2 billion CFU (spores) of strain MTCC 5856 once daily for 4 weeks to 90 days in adults. A 5-day children's trial used 400 million spores alongside oral rehydration and zinc.
Active Compound Live spores of Bacillus coagulans strain MTCC 5856 (Weizmannia coagulans), supplied by Sabinsa.

Benefits

Gas, bloating and abdominal comfort

In 70 adults with functional gas and bloating and no other gut diagnosis, strain MTCC 5856 at 2 billion spores a day for 4 weeks cut the gas and bloating score from about 9 to 3, versus about 9 to 8 on placebo, and overall self-ratings improved more. Other digestive scores fell in both groups. All authors work for the maker.

Bowel symptoms when taken alongside standard drug care

In a 90-day pilot in 36 people newly diagnosed with diarrhea-type IBS, strain MTCC 5856 (2 billion CFU a day) improved bloating, abdominal pain, diarrhea and stool frequency more than placebo, but every participant also took domperidone, esomeprazole and the antibiotic metronidazole. That makes it a disease-treatment result rather than evidence for healthy digestion. The maker ran it.

Mood rating scores in adults with low mood and digestive symptoms

In a 90-day pilot in 40 adults diagnosed with major depression and IBS who took no other medicines, strain MTCC 5856 (2 billion spores a day) left depression scores lower than placebo; change from baseline differed on two of three scales, with no correction for four primary outcomes. The maker sponsored it, only 60% fully complied by the end, and it is unrepeated. It does not show that a probiotic treats depression.

Heat and acid tolerance of the spores

In the maker's laboratory tests, MTCC 5856 spores held up to heating, cooking and simulated stomach acid better than the Lactobacillus strains they were compared with. None of the cited human trials measured how many spores survive storage or reach the intestine.

Gut bacteria in healthy adults

In a 28-day placebo-controlled trial in 30 healthy adults, the overall makeup of gut bacteria changed little, with small rises in a few groups such as Faecalibacterium and Ruminococcus, and abdominal comfort scores did not differ from placebo. Bacterial counts are a laboratory measure, not a health outcome. Five of the seven authors work for the maker.

Studied as an add-on to oral rehydration in children

In 110 children aged 1 to 10 with acute diarrhea, 400 million spores of MTCC 5856 given with oral rehydration and zinc for 5 days shortened diarrhea by about 11 hours versus placebo in a maker-run trial, though daily stool frequency did not differ. Diarrhea in young children needs medical care.

Mechanism of action

1

Spore germination and lactic acid production

B. coagulans is a lactic acid-producing bacterium. The proposed mechanism is that spores pass through the stomach, germinate in the intestine and produce lactic acid, which may favor beneficial bacteria. The cited human trials did not test this directly. In the healthy-adult trial, the amount of B. coagulans found in stool varied widely between people before and after the study, so how long it stays in the gut is unclear.

Clinical trials

1
MTCC 5856 Alongside Standard Drug Care: Pilot Randomized Trial
PubMed

Randomized, double-blind, placebo-controlled, three-center pilot of Bacillus coagulans strain MTCC 5856, 2 billion CFU/day for 90 days, taken at least 4 hours apart from standard drug care that both groups also took, chosen by the investigators: domperidone with esomeprazole, and the antibiotic metronidazole; participants were newly diagnosed with diarrhea-predominant IBS, and the symptom outcomes were bloating, vomiting, diarrhea, abdominal pain and stool frequency (Majeed et al. 2016, Nutr J).

36 newly diagnosed people at three centers in India (18 per group), all also taking prescription drugs.

The five symptom scores listed in the study details improved more than with placebo (p < 0.01), and quality of life rose. Because every participant also took prescription drugs, including an antibiotic, this is a disease-treatment result rather than evidence for healthy function. The trial was small and was run by the strain's maker, Sami Labs and Sabinsa.

2
MTCC 5856 for Functional Gas and Bloating: Randomized Placebo-Controlled Trial
PubMed

Randomized, double-blind, placebo-controlled trial at hospitals in southern India of strain MTCC 5856, 2 billion spores a day or placebo for 4 weeks; the two primary outcomes were the GSRS indigestion (gas and bloating) score and a patient global rating; registered CTRI/2019/06/019617; people using antibiotics or gut medicines were excluded; all authors are employees of Sami-Sabinsa or Sabinsa (Majeed et al. 2023, Medicine (Baltimore))

70 adults aged 18 to 65 meeting Rome IV criteria for functional abdominal bloating or distension (35 per group); 66 completed.

Both primary outcomes favored the probiotic, each at P < .001, which stays below a Bonferroni threshold of .025 for two outcomes: the gas and bloating score fell from 8.91 to 3.06 versus 9.42 to 8.43 on placebo, and the global rating improved more. Other GSRS scores fell within both groups, and stool type did not differ between groups. The abstract reports no adverse events, but the full text lists one probiotic user with mild acidity on two days and one episode of nausea or vomiting.

3
MTCC 5856 in Adults With Major Depression and IBS: Pilot Randomized Trial
PubMed

Randomized, double-blind, placebo-controlled, three-center pilot in India of strain MTCC 5856, 2 billion spores a day or placebo for 90 days; participants agreed to use no other medicines; the stated primary outcomes were the 90-day changes in the HAM-D, MADRS and CES-D depression scales and IBS quality of life, with no adjustment for testing four outcomes and no formal sample size calculation; registered CTRI/2015/05/005754; sponsored by Sabinsa, and all authors are Sabinsa or Sami Labs employees (Majeed et al. 2018, Food Nutr Res)

40 adults diagnosed with major depressive disorder and IBS (20 per group); no dropouts, but only 60% met full treatment compliance at the final visit.

At day 90, depression scores were lower than with placebo (HAM-D 5.9 versus 12.5, p = 0.005; MADRS 6.0 versus 12.6, p = 0.007; CES-D p = 0.009), as were IBS quality of life and gut discomfort scores. Comparing changes from baseline, the stated primary measure, HAM-D, MADRS and IBS quality of life differed (p 0.027 to 0.031), but CES-D (p = 0.051) and gut discomfort (p = 0.132) did not; none of these change comparisons would pass a Bonferroni correction for four primary outcomes (0.0125), while the day 90 comparisons would. The only adverse event, fever and weakness, was in the placebo group.

4
MTCC 5856 in Healthy Adults: Fecal Bacteria Over 28 Days
PubMed

Randomized, double-blind, placebo-controlled trial of LactoSpore (strain MTCC 5856, 2 billion CFU a day) or placebo for 28 days, with 16S sequencing of fecal samples; five of the seven authors are affiliated with Sami-Sabinsa or Sabinsa (Majeed et al. 2023, Medicine (Baltimore))

30 healthy adults in India.

Overall fecal bacterial makeup changed little; a few groups such as Prevotella, Faecalibacterium and Ruminococcus rose slightly with the strain. Abdominal Health Questionnaire scores did not differ from placebo, blood tests stayed normal, and no adverse events were reported. Counts of the strain in feces varied widely from person to person.

5
MTCC 5856 Added to Oral Rehydration and Zinc in Children
PubMed

Randomized, double-blind, placebo-controlled trial of strain MTCC 5856 (400 million spores) or placebo with oral rehydration solution and zinc for 5 days in children with acute diarrhea of any cause; the primary outcomes were the duration and daily frequency of diarrhea (Majeed et al. 2023, Front Pediatr).

110 non-hospitalized children aged 1 to 10, all given oral rehydration and zinc.

The illness lasted 51.3 hours with the strain versus 62.7 hours with placebo (p = 0.011), and dehydration status improved more. Daily episode frequency was lower but not significantly. Both groups also received oral rehydration and zinc. Most authors are employees of the maker.

Side effects and drug interactions

Common Potential side effects

The cited adult trials ran from 4 weeks to 90 days. Adverse events were few and mild: in the gas and bloating trial one person taking the strain had brief acidity and nausea, and in the children's trial mild stomach irritation was recorded in both groups. Longer use has not been studied.
If digestive symptoms persist or worsen after starting a probiotic, stop taking it and talk to a doctor.
According to NCCIH, the risk of harmful effects from probiotics is greater in people with severe illnesses or weakened immune systems, so they should talk to their doctor first. The FDA has warned that premature infants given probiotics are at risk of severe infections.
Diarrhea in infants and young children, or diarrhea with fever, blood or signs of dehydration, needs medical care. In children this strain was studied only as an add-on to oral rehydration and zinc.

Important Drug interactions

Antibiotics: in the diarrhea-type IBS trial the strain was taken at least 4 hours apart from standard drugs that included metronidazole; no trial tested whether antibiotics reduce its effect, so ask a pharmacist about timing.
Immunosuppressant medicines (for example after an organ transplant): NCCIH notes a higher risk of harmful effects from probiotics in people with weakened immune systems, so ask your doctor before taking one.
No drug interactions were formally studied in the cited trials; tell your doctor or pharmacist about any supplement you take.

Frequently asked questions about LactoSpore® (Heat-Stable Bacillus coagulans MTCC 5856 — Sabinsa)

Is LactoSpore the same as other Bacillus coagulans probiotics?

No. LactoSpore is strain MTCC 5856. Other Bacillus coagulans strains, such as Unique IS2 and GBI-30, 6086 (BC30), have their own separate trials, and results for one strain should not be assumed for another. Check that the label names the strain and gives the dose used in that strain's trials, which for adults was 2 billion spores a day.

What is LactoSpore?

LactoSpore from Sabinsa is one specific strain of the spore-forming, lactic acid-producing bacterium Bacillus coagulans, deposited as MTCC 5856 (newer papers call the species Weizmannia coagulans). Results for one probiotic strain do not carry over to another.

What is LactoSpore used for?

LactoSpore is researched primarily for Gut Health. In 70 adults with functional gas and bloating and no other gut diagnosis, strain MTCC 5856 at 2 billion spores a day for 4 weeks cut the gas and bloating score from about 9 to 3, versus about 9 to 8 on placebo, and overall self-ratings impr…

What is the recommended dosage of LactoSpore?

The clinically studied dose is 2 billion CFU (spores) of strain MTCC 5856 once daily for 4 weeks to 90 days in adults. A 5-day children's trial used 400 million spores alongside oral rehydration and zinc. Always follow the product label and check with a healthcare provider for personal advice.

Is LactoSpore safe, and does it have side effects?

Side effects and cautions reported for LactoSpore include: The cited adult trials ran from 4 weeks to 90 days. Adverse events were few and mild: in the gas and bloating trial one person taking the strain had brief acidity and nausea, and in the children's trial mild stomach irritation was recorded in both groups. It may also interact with some medications. LactoSpore is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does LactoSpore interact with any medications?

Possible interactions include: Antibiotics: in the diarrhea-type IBS trial the strain was taken at least 4 hours apart from standard drugs that included metronidazole; no trial tested whether antibiotics reduce its effect, so ask a pharmacist about timing. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for LactoSpore?

NutraSmarts rates the evidence for LactoSpore as Limited (2 out of 5). It is backed by 5 study summaries and 9 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(9 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Majeed M, Nagabhushanam K, Natarajan S, Sivakumar A, Ali F, Pande A, Majeed S, Karri SK. Bacillus coagulans MTCC 5856 supplementation in the management of diarrhea predominant Irritable Bowel Syndrome: a double blind randomized placebo controlled pilot clinical study. Nutr J. 2016;15:21. doi: 10.1186/s12937-016-0140-6.PubMedUsed to support: Randomized, double-blind, placebo-controlled pilot in 36 people newly diagnosed with diarrhea-predominant IBS, given strain MTCC 5856 (2 billion CFU/day) or placebo for 90 days. Both groups also took standard drug care: domperidone with esomeprazole, and the antibiotic metronidazole. Bloating, abdominal pain, diarrhea and stool frequency improved more than with placebo, and quality of life rose. Authors are from Sami Labs and Sabinsa, the strain's maker.
  2. Majeed M, Nagabhushanam K, Arumugam S, Majeed S, Ali F. Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, double-blind, placebo controlled, multi-centre, pilot clinical study. Food Nutr Res. 2018;62. doi: 10.29219/fnr.v62.1218.PubMedUsed to support: Randomized, double-blind, placebo-controlled, three-center pilot (CTRI/2015/05/005754) in 40 adults with major depressive disorder and IBS who agreed to take no other medicines: 2 billion spores a day of strain MTCC 5856 for 90 days left HAM-D, MADRS and CES-D depression scores and IBS quality of life lower than placebo at day 90 (p 0.005 to 0.010). For the stated primary measure, change from baseline, HAM-D, MADRS and IBS quality of life differed (p 0.027 to 0.031) but CES-D did not (p = 0.051), with no adjustment for four primary outcomes and no sample size calculation. Only 60% met full compliance at the final visit. Sponsored by Sabinsa, and all authors are Sabinsa or Sami Labs employees. Not evidence that a probiotic treats depression.
  3. Majeed M, Nagabhushanam K, Paulose S, Arumugam S, Mundkur L. The effects of Bacillus coagulans MTCC 5856 on functional gas and bloating in adults: A randomized, double-blind, placebo-controlled study. Medicine (Baltimore). 2023;102(9):e33109. doi: 10.1097/MD.0000000000033109.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial (CTRI/2019/06/019617) in 70 adults meeting Rome IV criteria for functional bloating or distension: 2 billion spores a day for 4 weeks lowered the GSRS indigestion score from 8.91 to 3.06 versus 9.42 to 8.43 on placebo and improved the patient global rating more, the two primary outcomes. The full text lists one probiotic user with mild acidity and nausea or vomiting. All authors are Sami-Sabinsa or Sabinsa employees.
  4. Majeed M, Nagabhushanam K, Mundkur L, Paulose S, Divakar H, Rao S, Arumugam S. Probiotic modulation of gut microbiota by Bacillus coagulans MTCC 5856 in healthy subjects: A randomized, double-blind, placebo-control study. Medicine (Baltimore). 2023;102(20):e33751. doi: 10.1097/MD.0000000000033751.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in 30 healthy adults: 2 billion CFU a day for 28 days caused minimal overall change in gut bacteria, with small increases in Prevotella, Faecalibacterium, Blautia, Megasphaera and Ruminococcus; Abdominal Health Questionnaire scores did not differ from placebo, and no adverse events were reported. Stool counts of B. coagulans varied widely. Five of the seven authors are Sami-Sabinsa or Sabinsa staff.
  5. Majeed M, Nagabhushanam K, Arumugam S, Chadalavada N, Seepana J, Annamalai T, Murali A, Prakasan P, Mundkur L. Probiotic Weizmannia coagulans MTCC 5856 as adjunct therapy in children's acute diarrhea-a randomized, double-blind, placebo-controlled study. Front Pediatr. 2023;11:1338126. doi: 10.3389/fped.2023.1338126.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial in 110 children aged 1 to 10 with acute diarrhea treated outside hospital, given strain MTCC 5856 (400 million spores) or placebo with oral rehydration and zinc for 5 days. Diarrhea lasted about 51 hours versus 63 hours on placebo (p = 0.011); daily frequency did not differ significantly. Most authors are Sami-Sabinsa employees. The full text lists mild gastric irritation as the only adverse event, in both groups, although the abstract reports none.
  6. Majeed M, Majeed S, Arumugam S, Ali F, Beede K. Comparative evaluation for thermostability and gastrointestinal survival of probiotic Bacillus coagulans MTCC 5856. Biosci Biotechnol Biochem. 2021;85(4):962-971. doi: 10.1093/bbb/zbaa116.PubMedUsed to support: Laboratory study by the maker (Sami Labs and Sabinsa): MTCC 5856 spores showed the highest heat resistance among the Bacillus and Lactobacillus strains tested, resisted simulated gastric juice better than Lactobacillus strains, and kept most of their viability through cooking flatbread and noodles and through pasteurization. No human data.
  7. Maslennikov R, Gosteeva E, Ananeva V, Korshunova L, Kravtsowa A, Poluektova E, Ulyanin A, Sigidaev A, Kikhasurova P, Ivashkin V. Strain-Specific Systematic Review with Meta-Analysis of Probiotics Efficacy in the Treatment of Irritable Bowel Syndrome. J Clin Med. 2026;15(3):1152. doi: 10.3390/jcm15031152.PubMedUsed to support: Strain-by-strain meta-analysis of single-strain probiotic trials in IBS (32 articles, 10 strains). For Bacillus coagulans MTCC 5856, two maker-run trials (the diarrhea-type IBS pilot, given with standard drug care, and the depression with IBS pilot) could be pooled only for quality of life, which improved versus placebo. No other MTCC 5856 outcome could be meta-analyzed.
  8. Xie P, Luo M, Deng X, Fan J, Xiong L. Outcome-Specific Efficacy of Different Probiotic Strains and Mixtures in Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis. Nutrients. 2023;15(17):3856. doi: 10.3390/nu15173856.PubMedUsed to support: Network meta-analysis of 81 probiotic RCTs (9,253 adults with IBS). Bacillus coagulans MTCC 5856 ranked among the most effective probiotics for abdominal pain (SUCRA 96.9%) and for stool form in diarrhea-type IBS (SUCRA 99.6%), but its only included trial was the maker-run diarrhea-type IBS pilot in which both groups also took standard drug care. Rankings compare many products indirectly and the authors call for confirmation.
  9. National Center for Complementary and Integrative Health (NCCIH). Probiotics: Usefulness and Safety. NCCIH (National Institutes of Health). 2019;Fact sheet, last updated August 2019. https://www.nccih.nih.gov/health/probiotics-what-you-need-to-know.SourceUsed to support: Not PubMed-indexed (US government fact sheet, read on the NCCIH site). States that the risk of harmful effects from probiotics is greater in people with severe illnesses or compromised immune systems, and that the FDA has warned that premature infants given probiotics are at risk of severe, potentially fatal infections.